{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:21:57Z","timestamp":1790684517893,"version":"4.1.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1002\/jps.23181","type":"journal-article","created":{"date-parts":[[2012,5,9]],"date-time":"2012-05-09T18:05:45Z","timestamp":1336586745000},"page":"3033-3046","source":"Crossref","is-referenced-by-count":59,"title":["Pharmaceutical Aspects of the Recombinant Human Serum Albumin Dimer: Structural Characteristics, Biological Properties, and Medical Applications"],"prefix":"10.1016","volume":"101","author":[{"given":"Kazuaki","family":"Taguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Tuan","family":"Giam Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Otagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1002\/jps.23181_bb0010","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/1869","article-title":"Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites","volume":"5","author":"Curry","year":"1998","journal-title":"Nat Struct Biol"},{"key":"10.1002\/jps.23181_bb0015","series-title":"Human serum albumin: New insight on its structural dynamics, functional impacts and pharmaceutical applications","first-page":"1","author":"Otagiri","year":"2011"},{"issue":"4","key":"10.1002\/jps.23181_bb0020","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1248\/bpb.32.527","article-title":"Pharmaceutically important pre- and posttranslational modifications on human serum albumin","volume":"32","author":"Otagiri","year":"2009","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"10.1002\/jps.23181_bb0025","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1742-4658.2004.04474.x","article-title":"Role of Tyr84 in controlling the reactivity of Cys34 of human albumin","volume":"272","author":"Stewart","year":"2005","journal-title":"FEBS J"},{"issue":"4","key":"10.1002\/jps.23181_bb0030","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1042\/cs0950459","article-title":"Administration of albumin to patients with sepsis syndrome: A possible beneficial role in plasma thiol repletion","volume":"95","author":"Quinlan","year":"1998","journal-title":"Clin Sci (Lond)"},{"issue":"3","key":"10.1002\/jps.23181_bb0035","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.CCM.0000114574.18641.5D","article-title":"Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury","volume":"32","author":"Quinlan","year":"2004","journal-title":"Crit Care Med"},{"issue":"1Pt 2","key":"10.1002\/jps.23181_bb0040","first-page":"H246","article-title":"gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis","volume":"262","author":"Schnitzer","year":"1992","journal-title":"Am J Physiol"},{"issue":"41","key":"10.1002\/jps.23181_bb0045","doi-asserted-by":"crossref","first-page":"25968","DOI":"10.1074\/jbc.272.41.25968","article-title":"Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway","volume":"272","author":"Tiruppathi","year":"1997","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1002\/jps.23181_bb0050","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1021\/nn9012274","article-title":"Size and dynamics of caveolae studied using nanoparticles in living endothelial cells","volume":"3","author":"Wang","year":"2009","journal-title":"ACS Nano"},{"issue":"17","key":"10.1002\/jps.23181_bb0055","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.2165\/00003495-200767170-00007","article-title":"Defining the role of insulin detemir in basal insulin therapy","volume":"67","author":"Morales","year":"2007","journal-title":"Drugs"},{"issue":"10","key":"10.1002\/jps.23181_bb0060","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1517\/14712598.2010.521494","article-title":"Albinterferon-alpha 2b: A new treatment option for hepatitis C","volume":"10","author":"Flisiak","year":"2010","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1002\/jps.23181_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/vhrm.2008.04.01.1","article-title":"Gadofosveset-enhanced magnetic resonance angiography","volume":"4","author":"Goyen","year":"2008","journal-title":"Vasc Health Risk Manag"},{"issue":"9","key":"10.1002\/jps.23181_bb0070","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3109\/15563650.2011.624102","article-title":"Use of the molecular adsorbent recirculating system (MARS) for the management of acute poisoning with or without liver failure","volume":"49","author":"Wittebole","year":"2011","journal-title":"Clin Toxicol (Phila)"},{"issue":"3","key":"10.1002\/jps.23181_bb0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00006231-200103000-00008","article-title":"99Tc(m) nanocolloid scintigraphy: A reliable way to detect active joint disease in patients with peripheral joint pain","volume":"22","author":"Adams","year":"2001","journal-title":"Nucl Med Commun"},{"issue":"5","key":"10.1002\/jps.23181_bb0080","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.athoracsur.2011.01.016","article-title":"Sentinel node identification using technetium\u201399m neomannosyl human serum albumin in esophageal cancer","volume":"91","author":"Kim","year":"2011","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"10.1002\/jps.23181_bb0085","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00003072-200104000-00002","article-title":"Lymphoscintigraphic sentinel node imaging and gamma probe detection in breast cancer with Tc\u201399m nanocolloidal albumin: results of an optimized protocol","volume":"26","author":"Rink","year":"2001","journal-title":"Clin Nucl Med"},{"issue":"5","key":"10.1002\/jps.23181_bb0090","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1177\/0091270010372626","article-title":"Pharmacokinetics of 5-aminofluorescein-albumin, a novel fluorescence marker of brain tumors during surgery","volume":"51","author":"Ding","year":"2011","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"10.1002\/jps.23181_bb0095","first-page":"1245","article-title":"CJC-1131. ConjuChem","volume":"4","author":"Giannoukakis","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"issue":"16","key":"10.1002\/jps.23181_bb0100","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1158\/1078-0432.CCR-06-2776","article-title":"Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin","volume":"13","author":"Unger","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1002\/jps.23181_bb0105","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1053\/j.gastro.2010.06.062","article-title":"Albinterferon alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3","volume":"139","author":"Nelson","year":"2010","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/jps.23181_bb0110","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1053\/j.gastro.2010.06.066","article-title":"Albinterferon alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 1","volume":"139","author":"Zeuzem","year":"2010","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/jps.23181_bb0115","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jconrel.2011.05.013","article-title":"Human serum albumin\u2013thioredoxin fusion protein with long blood retention property is effective in suppressing lung injury","volume":"154","author":"Furukawa","year":"2011","journal-title":"J Control Release"},{"issue":"11","key":"10.1002\/jps.23181_bb0120","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1023\/B:PHAM.0000048203.30568.81","article-title":"AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure","volume":"21","author":"Wang","year":"2004","journal-title":"Pharm Res"},{"issue":"5","key":"10.1002\/jps.23181_bb0125","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.biomaterials.2011.10.050","article-title":"Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types","volume":"33","author":"Bae","year":"2012","journal-title":"Biomaterials"},{"issue":"1\u20132","key":"10.1002\/jps.23181_bb0130","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ijpharm.2011.11.013","article-title":"Synthesis and biological evaluation of radiolabeled photosensitizer linked bovine serum albumin nanoparticles as a tumor imaging agent","volume":"422","author":"Ozgur","year":"2012","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1002\/jps.23181_bb0135","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.resuscitation.2008.04.020","article-title":"Volume resuscitation from hemorrhagic shock with albumin and hexaPEGylated human serum albumin","volume":"79","author":"Cabrales","year":"2008","journal-title":"Resuscitation"},{"issue":"2","key":"10.1002\/jps.23181_bb0140","doi-asserted-by":"crossref","first-page":"R54","DOI":"10.1186\/cc6874","article-title":"Survival time in severe hemorrhagic shock after perioperative hemodilution is longer with PEG-conjugated human serum albumin than with HES 130\/0.4: A microvascular perspective","volume":"12","author":"Martini","year":"2008","journal-title":"Crit Care"},{"key":"10.1002\/jps.23181_bb0145","doi-asserted-by":"crossref","first-page":"8388","DOI":"10.1021\/ma990826p","article-title":"Cross-linked human serum albumin dimer incorporating sixteen (tetraphenylporphinato)iron(II) derivatives: Synthesis, characterization, and O2-binding property","volume":"32","author":"Komatsu","year":"1999","journal-title":"Macromolecules"},{"issue":"5","key":"10.1002\/jps.23181_bb0150","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s11095-006-9933-1","article-title":"Recombinant human serum albumin dimer has high blood circulation activity and low vascular permeability in comparison with native human serum albumin","volume":"23","author":"Matsushita","year":"2006","journal-title":"Pharm Res"},{"issue":"38","key":"10.1002\/jps.23181_bb0155","doi-asserted-by":"crossref","first-page":"35035","DOI":"10.1074\/jbc.M205854200","article-title":"Albumin binding as a general strategy for improving the pharmacokinetics of proteins","volume":"277","author":"Dennis","year":"2002","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1002\/jps.23181_bb0160","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jconrel.2010.03.010","article-title":"Genetically engineered mannosylated-human serum albumin as a versatile carrier for liver-selective therapeutics","volume":"145","author":"Hirata","year":"2010","journal-title":"J Control Release"},{"issue":"1","key":"10.1002\/jps.23181_bb0165","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2006.11.015","article-title":"Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle","volume":"118","author":"Lu","year":"2007","journal-title":"J Control Release"},{"issue":"6","key":"10.1002\/jps.23181_bb0170","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/10611860902963013","article-title":"Brain delivery and systemic effect of cationic albumin conjugated PLGA nanoparticles","volume":"17","author":"Xu","year":"2009","journal-title":"J Drug Target"},{"issue":"Pt 2","key":"10.1002\/jps.23181_bb0175","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1042\/bj3290405","article-title":"One-electron oxidation pathway of thiols by peroxynitrite in biological fluids: Bicarbonate and ascorbate promote the formation of albumin disulphide dimers in human blood plasma","volume":"329","author":"Scorza","year":"1998","journal-title":"Biochem J"},{"issue":"2","key":"10.1002\/jps.23181_bb0180","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.bbrc.2005.11.183","article-title":"Formation of albumin dimers induced by exposure to peroxides in human plasma: A possible biomarker for oxidative stress","volume":"340","author":"Ogasawara","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1002\/jps.23181_bb0185","first-page":"233","article-title":"Alteration in plasma antioxidant capacity in various degrees of chronic renal failure","volume":"51","author":"Mimic-Oka","year":"1999","journal-title":"Clin Nephrol"},{"issue":"1","key":"10.1002\/jps.23181_bb0190","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000186208","article-title":"Trace elements and lipid peroxidation abnormalities in patients with chronic renal failure","volume":"57","author":"Richard","year":"1991","journal-title":"Nephron"},{"key":"10.1002\/jps.23181_bb0195","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1021\/ja01641a006","article-title":"Dimerization of serum mercaptalbumin in presence of mercurials. II. Studies with a bifunctional organic mercurial","volume":"76","author":"Edsall","year":"1954","journal-title":"J Am Chem Soc"},{"key":"10.1002\/jps.23181_bb0200","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1021\/ja01641a007","article-title":"A disulfide dimer of human mercaptalbumin1a,b","volume":"76","author":"Straessle","year":"1954","journal-title":"J Am Chem Soc"},{"issue":"2","key":"10.1002\/jps.23181_bb0205","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0005-2795(70)90178-9","article-title":"Hydrolysis of disulfide bonds in weakly alkaline media. II. Bovine serum albumin dimer","volume":"200","author":"Andersson","year":"1970","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"10.1002\/jps.23181_bb0210","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/0003-9861(81)90033-3","article-title":"Disruption of the tryptophan binding site in the human serum albumin dimer","volume":"207","author":"Sollenne","year":"1981","journal-title":"Arch Biochem Biophys"},{"key":"10.1002\/jps.23181_bb0215","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0065-3233(08)60640-3","article-title":"Structure of serum albumin","volume":"45","author":"Carter","year":"1994","journal-title":"Adv Protein Chem"},{"issue":"1","key":"10.1002\/jps.23181_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0003-9861(81)90250-2","article-title":"The environment of the sulfhydryl group in human plasma albumin as determined by spin labeling","volume":"209","author":"Cornell","year":"1981","journal-title":"Arch Biochem Biophys"},{"issue":"2\u20133","key":"10.1002\/jps.23181_bb0225","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1388-1981(99)00148-1","article-title":"Fatty acid binding to human serum albumin: New insights from crystallographic studies","volume":"1441","author":"Curry","year":"1999","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"10.1002\/jps.23181_bb0230","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/protein\/12.6.439","article-title":"Crystal structure of human serum albumin at 2.5 \u00c5 resolution","volume":"12","author":"Sugio","year":"1999","journal-title":"Protein Eng"},{"issue":"2","key":"10.1002\/jps.23181_bb0235","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.lab.2003.10.008","article-title":"A covalently linked recombinant albumin dimer is more rapidly cleared in vivo than are wild-type and mutant C34A albumin","volume":"143","author":"McCurdy","year":"2004","journal-title":"J Lab Clin Med"},{"issue":"1\u20133","key":"10.1002\/jps.23181_bb0240","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbagen.2004.08.010","article-title":"Physicochemical characterization of cross-linked human serum albumin dimer and its synthetic heme hybrid as an oxygen carrier","volume":"1675","author":"Komatsu","year":"2004","journal-title":"Biochim Biophys Acta"},{"issue":"9","key":"10.1002\/jps.23181_bb0245","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/protein\/14.9.711","article-title":"Stable linker peptides for a cellulose-binding domain\u2013lipase fusion protein expressed in Pichia pastoris","volume":"14","author":"Gustavsson","year":"2001","journal-title":"Protein Eng"},{"issue":"11","key":"10.1002\/jps.23181_bb0250","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.4049\/jimmunol.162.11.6589","article-title":"Characterization of scFv\u2013Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths","volume":"162","author":"Shan","year":"1999","journal-title":"J Immunol"},{"issue":"8","key":"10.1002\/jps.23181_bb0255","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/protein\/13.8.583","article-title":"Construction of a diabody (small recombinant bispecific antibody) using a refolding system","volume":"13","author":"Takemura","year":"2000","journal-title":"Protein Eng"},{"issue":"12","key":"10.1002\/jps.23181_bb0260","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1023\/A:1013391001141","article-title":"In vitro and in vivo properties of recombinant human serum albumin from Pichia pastoris purified by a method of short processing time","volume":"18","author":"Watanabe","year":"2001","journal-title":"Pharm Res"},{"key":"10.1002\/jps.23181_bb0265","series-title":"All about albumin, genetics, and medical application","first-page":"432","author":"Peter","year":"1996"},{"issue":"3","key":"10.1002\/jps.23181_bb0270","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/clinchem\/31.3.478","article-title":"An albumin dimer in urine","volume":"31","author":"Beilby","year":"1985","journal-title":"Clin Chem"},{"issue":"1","key":"10.1002\/jps.23181_bb0275","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0009-8981(85)90233-5","article-title":"The role of urea in albumin dimerisation in nephrotic urines","volume":"151","author":"Birtwistle","year":"1985","journal-title":"Clin Chim Acta"},{"issue":"6","key":"10.1002\/jps.23181_bb0280","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0026-895X(25)10691-3","article-title":"The characterization of two specific drug binding sites on human serum albumin","volume":"11","author":"Sudlow","year":"1975","journal-title":"Mol Pharmacol"},{"issue":"6","key":"10.1002\/jps.23181_bb0285","first-page":"1052","article-title":"Further characterization of specific drug binding sites on human serum albumin","volume":"12","author":"Sudlow","year":"1976","journal-title":"Mol Pharmacol"},{"issue":"2","key":"10.1002\/jps.23181_bb0290","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1021\/bi00866a039","article-title":"The structure of bovine serum albumin at low pH","volume":"5","author":"Bloomfield","year":"1966","journal-title":"Biochemistry"},{"issue":"12","key":"10.1002\/jps.23181_bb0295","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1021\/bi00852a018","article-title":"The hydrodynamic properties of bovine serum albumin monomer and dimer","volume":"7","author":"Squire","year":"1968","journal-title":"Biochemistry"},{"issue":"4","key":"10.1002\/jps.23181_bb0300","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2141.2004.05106.x","article-title":"Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits","volume":"126","author":"Sheffield","year":"2004","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1002\/jps.23181_bb0305","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1124\/dmd.109.031989","article-title":"Superior plasma retention of a cross-linked human serum albumin dimer in nephrotic rats as a new type of plasma expander","volume":"38","author":"Taguchi","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1002\/jps.23181_bb0310","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1021\/bc2005363","article-title":"S-Nitrosated human serum albumin dimer is not only a novel anti-tumor drug but also a potentiator for anti-tumor drugs with augmented EPR effects","volume":"23","author":"Ishima","year":"2012","journal-title":"Bioconjug Chem"},{"issue":"5","key":"10.1002\/jps.23181_bb0315","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/1097-0215(20010601)92:5<718::AID-IJC1257>3.0.CO;2-D","article-title":"Pre-clinical evaluation of a methotrexate\u2013albumin conjugate (MTX\u2013HSA) in human tumor xenografts in vivo","volume":"92","author":"Burger","year":"2001","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1002\/jps.23181_bb0320","first-page":"1917","article-title":"In vitro and in vivo antitumor activity of methotrexate conjugated to human serum albumin in human cancer cells","volume":"9","author":"Wosikowski","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1002\/jps.23181_bb0325","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1097\/01.CCM.0000142574.00425.E9","article-title":"Morbidity in hospitalized patients receiving human albumin: A meta-analysis of randomized, controlled trials","volume":"32","author":"Vincent","year":"2004","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1002\/jps.23181_bb0330","doi-asserted-by":"crossref","first-page":"149","DOI":"10.7326\/0003-4819-135-3-200108070-00007","article-title":"Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials","volume":"135","author":"Wilkes","year":"2001","journal-title":"Ann Intern Med"},{"issue":"7153","key":"10.1002\/jps.23181_bb0335","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/bmj.317.7153.235","article-title":"Human albumin administration in critically ill patients: Systematic review of randomised controlled trials. Cochrane Injuries Group Albumin Reviewers","volume":"317","author":"Reviewers","year":"1998","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/jps.23181_bb0340","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00540-010-1034-y","article-title":"Colloid solutions: A clinical update","volume":"24","author":"Niemi","year":"2010","journal-title":"J Anesth"},{"issue":"2","key":"10.1002\/jps.23181_bb0345","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.bjp.0705650","article-title":"Carrageenan-induced mouse paw oedema is biphasic, age-weight dependent and displays differential nitric oxide cyclooxygenase-2 expression","volume":"142","author":"Posadas","year":"2004","journal-title":"Br J Pharmacol"},{"issue":"7","key":"10.1002\/jps.23181_bb0350","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1248\/bpb1978.3.345","article-title":"Comparative study between steroidal and nonsteroidal anti-inflammatory drugs on the mode of their actions on vascular permeability in rat carrageenin-air-pouch inflammation","volume":"3","author":"Sato","year":"1980","journal-title":"J Pharmacobiodyn"},{"issue":"2","key":"10.1002\/jps.23181_bb0355","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1152\/physrev.00055.2006","article-title":"Properties of the glomerular barrier and mechanisms of proteinuria","volume":"88","author":"Haraldsson","year":"2008","journal-title":"Physiol Rev"},{"issue":"1","key":"10.1002\/jps.23181_bb0360","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jconrel.2011.09.069","article-title":"Impact of albumin on drug delivery\u2014New applications on the horizon","volume":"157","author":"Elsadek","year":"2012","journal-title":"J Control Release"},{"issue":"9","key":"10.1002\/jps.23181_bb0365","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1021\/jm9909645","article-title":"Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration","volume":"43","author":"Knudsen","year":"2000","journal-title":"J Med Chem"},{"issue":"5","key":"10.1002\/jps.23181_bb0370","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2337\/diabetes.53.5.1187","article-title":"One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes","volume":"53","author":"Degn","year":"2004","journal-title":"Diabetes"},{"issue":"2","key":"10.1002\/jps.23181_bb0375","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.niox.2008.04.026","article-title":"Solid tumor physiology and hypoxia-induced chemo\/radio-resistance: Novel strategy for cancer therapy: Nitric oxide donor as a therapeutic enhancer","volume":"19","author":"Yasuda","year":"2008","journal-title":"Nitric Oxide"},{"issue":"4","key":"10.1002\/jps.23181_bb0380","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.2005.04.0436","article-title":"Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB\/IV non-small-cell lung cancer","volume":"24","author":"Yasuda","year":"2006","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1002\/jps.23181_bb0385","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0891-5849(00)00248-3","article-title":"Biological chemistry and clinical potential of S-nitrosothiols","volume":"28","author":"Hogg","year":"2000","journal-title":"Free Radic Biol Med"},{"issue":"4 Suppl 4","key":"10.1002\/jps.23181_bb0390","first-page":"3","article-title":"Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer","volume":"14","author":"Hryniuk","year":"1987","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1002\/jps.23181_bb0395","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1472-8206.2003.00125.x","article-title":"The therapeutic potential of NO-NSAIDs","volume":"17","author":"Wallace","year":"2003","journal-title":"Fundam Clin Pharmacol"},{"issue":"1","key":"10.1002\/jps.23181_bb0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10715760000300011","article-title":"A chemiluminescense-based assay for S-nitrosoalbumin and other plasma S-nitrosothiols","volume":"32","author":"Marley","year":"2000","journal-title":"Free Radic Res"},{"issue":"50","key":"10.1002\/jps.23181_bb0405","doi-asserted-by":"crossref","first-page":"34966","DOI":"10.1074\/jbc.M807009200","article-title":"S-nitrosylated human serum albumin-mediated cytoprotective activity is enhanced by fatty acid binding","volume":"283","author":"Ishima","year":"2008","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1002\/jps.23181_bb0410","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.niox.2009.09.003","article-title":"Nitrosylated human serum albumin (SNO-HSA) induces apoptosis in tumor cells","volume":"22","author":"Katayama","year":"2010","journal-title":"Nitric Oxide"},{"issue":"1","key":"10.1002\/jps.23181_bb0415","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1124\/jpet.107.132100","article-title":"Design and evaluation of S-nitrosylated human serum albumin as a novel anticancer drug","volume":"325","author":"Katayama","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"issue":"1\u20132","key":"10.1002\/jps.23181_bb0420","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review","volume":"65","author":"Maeda","year":"2000","journal-title":"J Control Release"},{"issue":"1\u20132","key":"10.1002\/jps.23181_bb0425","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijpharm.2003.09.050","article-title":"Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME)","volume":"277","author":"Tanaka","year":"2004","journal-title":"Int J Pharm"},{"issue":"12","key":"10.1002\/jps.23181_bb0430","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1111\/j.1349-7006.2009.01323.x","article-title":"Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application","volume":"100","author":"Seki","year":"2009","journal-title":"Cancer Sci"},{"issue":"8","key":"10.1002\/jps.23181_bb0435","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrm1703","article-title":"Transcriptional regulation and transformation by Myc proteins","volume":"6","author":"Adhikary","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7","key":"10.1002\/jps.23181_bb0440","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1158\/1078-0432.CCR-06-1807","article-title":"Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling","volume":"13","author":"Frederiksen","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1002\/jps.23181_bb0445","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/ijc.10786","article-title":"Potentiation of radiation-induced regrowth delay by isosorbide dinitrate in FSaII murine tumors","volume":"103","author":"Jordan","year":"2003","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1002\/jps.23181_bb0450","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1006\/niox.1996.0108","article-title":"Nitric oxide and some nitric oxide donor compounds enhance the cytotoxicity of cisplatin","volume":"1","author":"Wink","year":"1997","journal-title":"Nitric Oxide"},{"issue":"8","key":"10.1002\/jps.23181_bb0455","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1590\/S1807-59322009000800016","article-title":"A review of blood substitutes: Examining the history, clinical trial results, and ethics of hemoglobin-based oxygen carriers","volume":"64","author":"Chen","year":"2009","journal-title":"Clinics (Sao Paulo)"},{"issue":"9","key":"10.1002\/jps.23181_bb0460","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1517\/14712598.8.9.1425","article-title":"HBOC-201, hemoglobin glutamer-250 (bovine), Hemopure (Biopure Corporation)","volume":"8","author":"Jahr","year":"2008","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"10.1002\/jps.23181_bb0465","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1525-1594.2008.00698.x","article-title":"Review of hemoglobin-vesicles as artificial oxygen carriers","volume":"33","author":"Sakai","year":"2009","journal-title":"Artif Organs"},{"issue":"9","key":"10.1002\/jps.23181_bb0470","first-page":"1009","article-title":"Hemospan: A hemoglobin-based oxygen carrier for potential use as a blood substitute and for the potential treatment of critical limb ischemia","volume":"9","author":"Smani","year":"2008","journal-title":"Curr Opin Investig Drugs"},{"issue":"6831","key":"10.1002\/jps.23181_bb0475","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/35073775","article-title":"Blood product from cattle wins approval for use in humans","volume":"410","author":"Lok","year":"2001","journal-title":"Nature"},{"issue":"4","key":"10.1002\/jps.23181_bb0480","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/bc9700906","article-title":"Properties of and oxygen binding by albumin\u2013tetraphenylporphyrinatoiron(II) derivative complexes","volume":"8","author":"Tsuchida","year":"1997","journal-title":"Bioconjug Chem"},{"issue":"3","key":"10.1002\/jps.23181_bb0485","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1021\/bc010067r","article-title":"Effect of heme structure on O(2)-binding properties of human serum albumin\u2013heme hybrids: Intramolecular histidine coordination provides a stable O(2)-adduct complex","volume":"13","author":"Komatsu","year":"2002","journal-title":"Bioconjug Chem"},{"issue":"5","key":"10.1002\/jps.23181_bb0490","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1021\/bc990019v","article-title":"Human serum albumin incorporating tetrakis(o-pivalamido) phenylporphinatoiron(II) derivative as a totally synthetic O2-carrying hemoprotein","volume":"10","author":"Tsuchida","year":"1999","journal-title":"Bioconjug Chem"},{"issue":"2","key":"10.1002\/jps.23181_bb0495","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/jbm.a.10573","article-title":"Compatibility in vitro of albumin\u2013heme (O(2) carrier) with blood cell components","volume":"66","author":"Huang","year":"2003","journal-title":"J Biomed Mater Res A"},{"issue":"2","key":"10.1002\/jps.23181_bb0500","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/jbm.a.10324","article-title":"Human serum albumin incorporating synthetic heme: Red blood cell substitute without hypertension by nitric oxide scavenging","volume":"64","author":"Tsuchida","year":"2003","journal-title":"J Biomed Mater Res A"},{"issue":"4","key":"10.1002\/jps.23181_bb0505","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/jbm.a.30200","article-title":"Exchange transfusion with synthetic oxygen-carrying plasma protein \u201calbumin\u2013heme\u201d into an acute anemia rat model after seventy-percent hemodilution","volume":"71","author":"Komatsu","year":"2004","journal-title":"J Biomed Mater Res A"},{"issue":"1","key":"10.1002\/jps.23181_bb0510","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1021\/bc990065v","article-title":"Exchange transfusion with albumin\u2013heme as an artificial O2-infusion into anesthetized rats: Physiological responses, O2-delivery, and reduction of the oxidized hemin sites by red blood cells","volume":"11","author":"Tsuchida","year":"2000","journal-title":"Bioconjug Chem"},{"issue":"6","key":"10.1002\/jps.23181_bb0515","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/j.1349-7006.2008.00811.x","article-title":"Enhanced radiation response of a solid tumor with the artificial oxygen carrier \u2018albumin\u2013heme\u2019","volume":"99","author":"Horinouchi","year":"2008","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1002\/jps.23181_bb0520","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/jbm.a.10323","article-title":"Oxygenation of hypoxic region in solid tumor by administration of human serum albumin incorporating synthetic hemes","volume":"64","author":"Kobayashi","year":"2003","journal-title":"J Biomed Mater Res A"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915314490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915314490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T17:57:23Z","timestamp":1743098243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915314490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":103,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0022354915314490"],"URL":"https:\/\/doi.org\/10.1002\/jps.23181","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}